Forecast

The analysts' average price target is €48.83 (+33.89%). The median is €48.31 (+32.47%).

Buy	12
Hold	4
Sell	0

News Go to news feed

UroGen: launch of Zusduri shows strong early momentum

At the Cantor Fitzgerald conference, UroGen reported a robust early launch of its bladder cancer therapy Zusduri, with sales rising from $29.8m in Q1 to $50m in Q2 2025 and insured access exceeding 95%. The company sees a conservative peak sales potential of around $1.2bn and holds $180m in cash, which management says should be sufficient to reach profitability. UroGen is expanding its sales team and focusing on physician training and reimbursement, but still faces challenges in education, competitive pressure and converting initial momentum into sustainable growth. In parallel, UroGen is advancing follow-on programs such as UGN-103, UGN-104 and UGN-501; an NDA for UGN-103 has been submitted and an FDA decision is expected by mid‑June 2026. » More on de.investing.com
UroGen: market launch of ZUSDURI accelerates thanks to permanent J-code, pipeline expanded

At the Wells Fargo Healthcare Conference, UroGen reported growing commercial momentum for ZUSDURI after the assignment of a permanent J-code and 96% payer coverage. The company cites 450 prescribing physicians, roughly 1,500 activated treatment centers, and reiterates a peak sales potential of $1.2 billion for low- to intermediate-grade NMIBC, with a total upside of more than $2 billion if expanded to high-grade tumors. UroGen highlights ZUSDURI’s strong clinical profile, plans to expand into office-based practices, and is advancing next-generation candidates such as UGN-103, UGN-104 and UGN-501, as well as a collaboration with IntraGel to extend the product lifecycle. » More on de.investing.com
IntraGel receives up to $7 million from UroGen for TumoCure Phase 2

IntraGel has entered into an equity investment as well as options and research license agreement with UroGen for up to $7 million to fund the Phase 2 development of TumoCure, a local cisplatin therapy for advanced head and neck cancer based on the SRGel platform. UroGen obtains an exclusive option on worldwide development and commercialization rights after completion of the Phase 2 study, as well as access to the SRGel platform and options to license up to three additional oncology programs. Phase 1b data showed good tolerability, low systemic cisplatin exposure and initial signs of antitumor activity, including in cisplatin-resistant patients. » More on de.investing.com

Financials

In the last quarter, UROGEN PHARMA LTD had revenue of €63.49m and net profit of -€12.57m

(EUR)	June 2026	YoY
Revenue	63.49m	209.02%
Gross profit	57.73m	229.26%
Net profit	-12.57m	70.32%
EBITDA	-3.29m	92.05%

Fundamentals

Metric	Value
Market capitalization	€1.78bn
Number of shares	48.72m
52-week high/low	€43.83 - €13.68
Dividends	No
Beta	1.58
P/E ratio	-21.33
PEG ratio	-0.42
P/B ratio	-16.07
P/S ratio	10.90

Company profile

UroGen Pharma Ltd. ist ein Biotechnologieunternehmen, das sich mit der Entwicklung und Vermarktung neuartiger Lösungen für spezielle Krebsarten und Urothelerkrankungen befasst. Das Unternehmen bietet RTGel, ein polymeres, biokompatibles Hydrogel mit umgekehrter thermischer Gelierung zur Verbesserung des therapeutischen Profils bestehender Medikamente, sowie Jelmyto für die Pyelokalyzeal-Lösung an. Der führende Produktkandidat des Unternehmens ist UGN-102, der sich in klinischen Phase-III-Studien zur Behandlung verschiedener Formen von nicht-muskelinvasivem Urothelkarzinom befindet, darunter niedriggradiges Urothelkarzinom des oberen Trakts und niedriggradiger nicht-muskelinvasiver Blasenkrebs. Außerdem entwickelt es UGN-301 zur Behandlung von hochgradigem nicht-muskelinvasivem Blasenkrebs. Das Unternehmen hat eine Lizenzvereinbarung mit Allergan Pharmaceuticals International Limited für die Entwicklung und Vermarktung von pharmazeutischen Produkten, die RTGel und Clostridien-Toxine enthalten; mit Agenus Inc. für die Entwicklung, Herstellung, Verwendung, den Verkauf, Import und die Vermarktung von Produkten von Agenus für die Behandlung von Krebserkrankungen des Harntrakts durch intravesikale Verabreichung; und eine strategische Forschungskooperation mit MD Anderson, um die Behandlung von hochgradigem Blasenkrebs voranzutreiben. UroGen Pharma Ltd. wurde im Jahr 2004 gegründet und hat seinen Sitz in Princeton, New Jersey.